SCDC Released New Fact Sheets on Crizanlizumab, L-glutamine, & Voxelotor

SCDC Released New Fact Sheets on Crizanlizumab, L-glutamine, & Voxelotor

Posted on


The Sickle Cell Disease Coalition (SCDC) recently released SCD Therapy Fact Sheets to offer high-quality, vetted information on SCD treatments approved for use in the U.S. by the U.S. Food & Drug Administration (FDA): Crizanlizumab, L-glutamine, and Voxelotor. The fact sheets are written at a secondary reading level and are designed to help people living with SCD and their caregivers explore treatment options with their health care team. Access the fact sheets here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Name *

This site uses Akismet to reduce spam. Learn how your comment data is processed.